Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 1 Jan 2023 to 20 Jan 2023.
    • 22 Feb 2018 Planned primary completion date changed from 1 May 2018 to 20 May 2018.
    • 25 Jan 2017 Planned End Date changed from 1 Nov 2020 to 1 Jan 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top